Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO				Complete if Kn wn			
				Applicati n Number	10/054,638		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	01/22/2003 Robert P. Ryall		
				First Named Inventor			
	(llea as many sho	ate se n	acassani)	Art Unit	1645		
(Use as many sheets as necessary)				Examiner Name	Devi, Sarvamangala		
Sheet	2	of	2	Attorney Docket Number	API-01-059-US		

Examiner Initials*	Cite No. ¹	OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						
/S.D./		GIEBINK G S ET AL: Pneumococcal capsular polysaccharide-meningococcal outer membrane protein complex conjugate vaccines: Immunogenicity and efficacy in experimental pneumococcal otitis media: The Journal of Infectious diseases, vol 167, no 2, February 1993, pages 347-355						
/S.D./-		CAMPAGNE G. ET AL: Safety and Immunogenicity of three doses of a Neisseria meningitidis A+ diphtheria conjugate vaccine in infants from Niger: Pediatric Infectious Disease Journal, Vol 19, no 2 Pages 144-150 2 0 0 0						
/S.D./		PAOLETTI L C ET AL: Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polys accharide-tetanus toxoid conjugate vaccine: Infection and Immunity, Vol 62, no 8 Pages 3236-3243 , 1994						
San	A STATE OF THE STA							
,								
• •	-							
•								
			NO STATE OF THE ST					

Examiner	/S. Devi/	Date	03/22/2011
Signature		Considered	00/22/2011

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.